United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Legal & General Group Plc

Legal & General Group Plc trimmed its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 28.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 173,759 shares of the biotechnology company's stock after selling 69,066 shares during the period. Legal & General Group Plc owned about 0.39% of United Therapeutics worth $61,309,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Newbridge Financial Services Group Inc. acquired a new stake in United Therapeutics during the fourth quarter valued at $25,000. Millstone Evans Group LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB raised its holdings in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp boosted its position in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $131,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the subject of a number of research analyst reports. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $388.25.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. This represents a 23.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $955,319.67. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 80,500 shares of company stock valued at $27,849,960. Insiders own 11.90% of the company's stock.

United Therapeutics Stock Up 0.0 %

UTHR stock traded up $0.12 during midday trading on Thursday, hitting $285.31. The company's stock had a trading volume of 64,000 shares, compared to its average volume of 451,816. United Therapeutics Co. has a 52-week low of $232.84 and a 52-week high of $417.82. The firm has a 50-day simple moving average of $319.20 and a 200-day simple moving average of $349.67. The firm has a market capitalization of $12.81 billion, a P/E ratio of 12.48, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter last year, the business posted $4.36 EPS. On average, sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.